comparemela.com

Page 9 - Idorsia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Idorsia presents at the 41st J P Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 9, 2023 Idorsia Ltd today announced that Jean-Paul Clozel, Chief Executive Officer of Idorsia, will present at the. | January 9, 2023

United statesUnited kingdomSwitzerland generalSan franciscoAndrewc weissNeurocrine biosciencesJean paul clozelIdorsia ltdHead of investor relations corporate communicationsScripts national preferred formularyIdorsia pharmaceuticals ltdDrug administrationSwiss exchangeChief executive officerHealthcare conferenceStandard time

Idorsia Pharmaceuticals Ltd: Swissmedic approves QUVIVIQ (daridorexant) - a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

QUVIVIQ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ, Switzerland's first

United statesUnited kingdomSwitzerland generalGreat britainAndrewc weissJean paul clozelAlice huismanJ clin pharmacolIdorsia ltdAmerican psychiatric associationHead of investor relations corporate communicationsEuropean commission decision reliance procedureEuropean commissionDrug administrationSwiss exchangeRegulatory agency

Idorsia Pharmaceuticals Ltd: Idorsia and Simcere enter into a licensing agreement for daridorexant in China

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland & Nanjing, China - November 16, 2022 Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and

United statesHong kongUnited kingdomSwitzerland generalGreat britainAndrewc weissJinsheng renJean paul clozelJ clin pharmacolIdorsia ltdAmerican psychiatric associationHead of investor relations corporate communicationsSimcere pharmaceutical groupEuropean commission decision reliance procedureEuropean commissionDrug administration

Idorsia Pharmaceuticals Ltd: Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award

Martine Clozel was selected for the Prix Suisse award for her contribution to research, science, and medicine and was presented with the Prix Suisse by the National Council President Irène KälinThe Prix

Switzerland generalAndrewc weissPrix suisseStefan linderPeter spuhlerJean paul clozelWalter fischliMartine clozelThomas widmannIdorsia ltdStadler rail groupHead of investor relations corporate communicationsHead of initiative switzerlandFg pfister holdingNational council of switzerlandInitiative switzerland

Idorsia Pharmaceuticals Ltd: The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension

The Lancet reports that in patients with resistant hypertension, aprocitentan was well-tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40Upon approval

Western australiaUnited statesRheinland pfalzSwitzerland generalAndrewc weissClozelm aprocitentanArthurc corcoranJean paul clozelMarkus schlaichMartine clozelJ physiol pharmacolArterioscler thromb vascIdorsia ltdAmerican heart associationHead of investor relations corporate communicationsEuropean society of hypertension

vimarsana © 2020. All Rights Reserved.